Metyrapone

Drug Profile

Metyrapone

Alternative Names: SU 4885

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer HRA Pharma; Novartis
  • Class Antidepressants; Antihormones; Diagnostic agents; Pyridines
  • Mechanism of Action Steroid 11-beta-hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Adrenal insufficiency; Cushing syndrome; Hyperaldosteronism

Most Recent Events

  • 21 Jun 2016 HRA pharma completes phase I trials in Adrenal gland disorders (CCRN2134; 14445)
  • 26 Nov 2014 HRA Pharma plans a phase III trial for Cushing's syndrome (Treatment-experienced) in Italy, Belgium, USA, Germany and Spain (NCT02297945)
  • 06 Aug 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top